suramin has been researched along with mitoxantrone in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Kantoff, PW | 1 |
| Kelly, WK; Scher, HI; Steineck, G | 1 |
| Moore, MJ; Siu, LL | 1 |
| Beedassy, A; Cardi, G | 1 |
| Roth, BJ | 1 |
| Knox, JJ; Moore, MJ | 1 |
| Heicappell, R | 1 |
| Caccialanza, G; Carotti, A; Catto, M; Colombo, R; De Lorenzi, E; Lanni, C; Racchi, M; Verga, L | 1 |
| Connell, GJ; Liang, S | 1 |
| Field, RA; Maxwell, A; Mitchenall, LA; Rejzek, M; Taylor, JA | 1 |
7 review(s) available for suramin and mitoxantrone
| Article | Year |
|---|---|
New agents in the therapy of hormone-refractory patients with prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Male; Mitoxantrone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Suramin; Survival Analysis | 1995 |
Hormone-refractory (D3) prostate cancer: refining the concept.
Topics: Aminoglutethimide; Clinical Trials as Topic; Cortisone; Dexamethasone; Drug Therapy, Combination; Humans; Hydrocortisone; Male; Medroxyprogesterone; Mitoxantrone; Neoplasm Recurrence, Local; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Suramin; Treatment Outcome | 1995 |
Other chemotherapy regimens including mitoxantrone and suramin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Palliative Care; Prostatic Neoplasms; Suramin | 1997 |
Chemotherapy in advanced prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Doxorubicin; Estramustine; Humans; Liposomes; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Palliative Care; Prostatic Neoplasms; Suramin | 1999 |
Androgen-independent prostate cancer: not so chemorefractory after all.
Topics: Antineoplastic Combined Chemotherapy Protocols; Estramustine; Humans; Male; Mitoxantrone; Prostatic Neoplasms; Suramin | 1999 |
Treatment of hormone refractory prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Humans; Male; Mitoxantrone; Pain; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Suramin | 2001 |
Controversies in chemotherapy of prostate cancer.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgen Antagonists; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Trials as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Paclitaxel; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Suramin; Taxoids; Testosterone; Treatment Outcome | 2002 |
6 other study(ies) available for suramin and mitoxantrone
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Benzothiazoles; Cell Line, Tumor; Cell Survival; Electrophoresis, Capillary; Humans; Isoquinolines; Microscopy, Electron, Transmission; Mitoxantrone; Neuroprotective Agents; Particle Size; Peptide Fragments; Plaque, Amyloid; Protein Multimerization; Spectrometry, Fluorescence; Suramin; Thiazoles | 2009 |
Identification of specific inhibitors for a trypanosomatid RNA editing reaction.
Topics: Antiprotozoal Agents; False Positive Reactions; High-Throughput Screening Assays; Indoles; Inhibitory Concentration 50; Mitoxantrone; Models, Biological; Parasitic Sensitivity Tests; Phenols; Protein Synthesis Inhibitors; Protoporphyrins; RNA Editing; Sphingosine; Substrate Specificity; Suramin; Trypanosomatina | 2010 |
Application of a novel microtitre plate-based assay for the discovery of new inhibitors of DNA gyrase and DNA topoisomerase VI.
Topics: Anthraquinones; Arabidopsis; Archaeal Proteins; DNA Topoisomerases, Type II; Drug Evaluation, Preclinical; Escherichia coli; Hexylresorcinol; Methanosarcina; Mitoxantrone; Quinacrine; Sulfolobus; Suramin; Topoisomerase II Inhibitors; Topoisomerase Inhibitors | 2013 |